MedPath

SCT-200

Generic Name
SCT-200

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1
Recruiting
Conditions
Head and Neck Squamous Carcinoma
Interventions
First Posted Date
2022-09-23
Last Posted Date
2022-09-23
Lead Sponsor
Sinocelltech Ltd.
Target Recruit Count
120
Registration Number
NCT05552807
Locations
🇨🇳

Shanghai East Hospital, Shanghai, China

Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

Phase 2
Conditions
Oropharyngeal Carcinoma
Interventions
First Posted Date
2020-08-11
Last Posted Date
2022-04-04
Lead Sponsor
Fudan University
Target Recruit Count
52
Registration Number
NCT04508829
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

Phase 1
Conditions
Healthy Volunteers
Interventions
First Posted Date
2019-03-20
Last Posted Date
2019-03-20
Lead Sponsor
Dragonboat Biopharmaceutical Company Limited
Target Recruit Count
84
Registration Number
NCT03881787
Locations
🇨🇳

Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

🇨🇳

West China Hospital, Chengdu, Sichuang, China

SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma

Phase 2
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2019-03-14
Last Posted Date
2020-05-27
Lead Sponsor
Sinocelltech Ltd.
Target Recruit Count
25
Registration Number
NCT03874741
Locations
🇨🇳

Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

Phase 1
Conditions
Advanced Squamous Non-small Cell Lung Cancer
Interventions
First Posted Date
2019-01-17
Last Posted Date
2019-01-17
Lead Sponsor
Sinocelltech Ltd.
Target Recruit Count
50
Registration Number
NCT03808701

SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma

Phase 2
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2018-11-16
Last Posted Date
2018-11-16
Lead Sponsor
Shi Yuankai
Target Recruit Count
30
Registration Number
NCT03744208

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

Phase 2
Conditions
Head and Neck Cancer
Interventions
First Posted Date
2018-10-19
Last Posted Date
2020-03-23
Lead Sponsor
Sinocelltech Ltd.
Target Recruit Count
40
Registration Number
NCT03713372
Locations
🇨🇳

Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China

A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

Phase 1
Conditions
Colorectal Cancer
Interventions
First Posted Date
2018-04-09
Last Posted Date
2019-10-31
Lead Sponsor
Dragonboat Biopharmaceutical Company Limited
Target Recruit Count
18
Registration Number
NCT03491709
Locations
🇨🇳

Shanghai East Hospital Phase 1 Clinical Trial Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath